Michael Zilly

490 total citations
17 papers, 376 citations indexed

About

Michael Zilly is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Michael Zilly has authored 17 papers receiving a total of 376 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 10 papers in Epidemiology and 6 papers in Virology. Recurrent topics in Michael Zilly's work include HIV/AIDS drug development and treatment (12 papers), Pneumocystis jirovecii pneumonia detection and treatment (8 papers) and HIV Research and Treatment (6 papers). Michael Zilly is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), Pneumocystis jirovecii pneumonia detection and treatment (8 papers) and HIV Research and Treatment (6 papers). Michael Zilly collaborates with scholars based in Germany and Austria. Michael Zilly's co-authors include Peter Langmann, Hartwig Klinker, Benedikt Weißbrich, Ralf Winzer, Steffen Desch, Ernst Richter, Jörg Schubert, Franz Tollmann, Friedrich Kluge and Andreas Benesic and has published in prestigious journals such as Journal of Chromatography B, Infection and Annals of Clinical Microbiology and Antimicrobials.

In The Last Decade

Michael Zilly

17 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Zilly Germany	12	281	169	97	73	61	17	376
Catherine Knupp United States	7	320 1.1×	232 1.4×	170 1.8×	54 0.7×	39 0.6×	9	471
Andrew Luber United States	9	315 1.1×	167 1.0×	120 1.2×	39 0.5×	40 0.7×	22	395
C. J. L. la Porte Canada	11	433 1.5×	201 1.2×	137 1.4×	91 1.2×	129 2.1×	16	546
Anne Marie Taburet France	11	274 1.0×	206 1.2×	72 0.7×	38 0.5×	40 0.7×	20	419
Rosa Ruiz-Valderas Spain	12	342 1.2×	160 0.9×	189 1.9×	35 0.5×	52 0.9×	26	457
Clotilde Le Tiec France	8	330 1.2×	216 1.3×	78 0.8×	66 0.9×	74 1.2×	10	432
James A. McDowell United States	11	370 1.3×	258 1.5×	99 1.0×	75 1.0×	99 1.6×	15	546
Elgin Green United States	6	224 0.8×	111 0.7×	74 0.8×	127 1.7×	55 0.9×	9	378
Monique M. R. de Maat Netherlands	10	431 1.5×	229 1.4×	118 1.2×	100 1.4×	121 2.0×	15	606
Patricia K. Mydlow United States	6	205 0.7×	87 0.5×	131 1.4×	20 0.3×	72 1.2×	7	367

Countries citing papers authored by Michael Zilly

Since Specialization

Citations

This map shows the geographic impact of Michael Zilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Zilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Zilly more than expected).

Fields of papers citing papers by Michael Zilly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Zilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Zilly. The network helps show where Michael Zilly may publish in the future.

Co-authorship network of co-authors of Michael Zilly

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Zilly. A scholar is included among the top collaborators of Michael Zilly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Zilly. Michael Zilly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Langmann, Peter, Michael Zilly, Ralf Winzer, & Hartwig Klinker. (2006). Therapeutic Drug Monitoring: A Tool to Individualize Highly Active Antiretroviral Therapy in HIV Infected Patients. Current Pharmaceutical Analysis. 2(3). 205–217. 1 indexed citations

Winzer, Ralf, Peter Langmann, Michael Zilly, et al.. (2005). No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients. Annals of Clinical Microbiology and Antimicrobials. 4(1). 3–3. 25 indexed citations

Tappe, Dennis, Peter Langmann, Michael Zilly, et al.. (2004). Osteomyelitis and skin ulcers caused by Mycobacterium szulgai in an AIDS patient. Scandinavian Journal of Infectious Diseases. 36(11-12). 883–885. 19 indexed citations

Benesic, Andreas, Michael Zilly, Friedrich Kluge, et al.. (2004). Lipid Lowering Therapy with Fluvastatin and Pravastatin in Patients with HIV Infection and Antiretroviral Therapy: Comparison of Efficacy and Interaction with Indinavir. Infection. 32(4). 229–33. 53 indexed citations

Zilly, Michael, Peter Langmann, Ralf Winzer, et al.. (2004). Liquid chromatographic method for the determination of uridine in human serum. Journal of Chromatography B. 803(2). 345–351. 3 indexed citations

Langmann, Peter, et al.. (2004). Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART.. PubMed. 10(5). PI65–9. 2 indexed citations

Zilly, Michael, et al.. (2003). Highly sensitive gas chromatographic determination of ethanol in human urine samples. Journal of Chromatography B. 798(2). 179–186. 11 indexed citations

Winzer, Ralf, Peter Langmann, Michael Zilly, et al.. (2003). No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.. PubMed. 8(12). 531–4. 55 indexed citations

Langmann, Peter, et al.. (2002). Therapeutic Drug Monitoring of Indinavir in HIV-Infected Patients Undergoing HAART. Infection. 30(1). 13–16. 21 indexed citations

10.

Langmann, Peter, et al.. (2002). Rapid determination of nevirapine in human plasma by gas chromatography. Journal of Chromatography B. 767(1). 69–74. 11 indexed citations

11.

Langmann, Peter, et al.. (2002). Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.. PubMed. 7(7). 309–14. 33 indexed citations

12.

Zilly, Michael, et al.. (2002). Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.. PubMed. 7(4). 149–54. 17 indexed citations

13.

Langmann, Peter, et al.. (2001). High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy. Journal of Chromatography B Biomedical Sciences and Applications. 755(1-2). 151–156. 38 indexed citations

14.

Langmann, Peter, et al.. (2000). Influence of smoking on cotinine and caffeine plasma levels in patients with alcoholic liver cirrhosis.. PubMed. 5(5). 217–21. 13 indexed citations

15.

Langmann, Peter, et al.. (2000). Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.. PubMed. 5(2). 59–62. 19 indexed citations

16.

Langmann, Peter, et al.. (1999). High-performance liquid chromatographic method for the simultaneous determination of HIV-1 protease inhibitors indinavir, saquinavir and ritonavir in plasma of patients during highly active antiretroviral therapy. Journal of Chromatography B Biomedical Sciences and Applications. 735(1). 41–50. 36 indexed citations

17.

Klinker, Hartwig, Peter Langmann, Michael Zilly, & Ernst Richter. (1998). Drug monitoring during the treatment of AIDS‐associated Pneumocystis carinii pneumonia with trimethoprim‐sulfamethoxazole. Journal of Clinical Pharmacy and Therapeutics. 23(2). 149–154. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact